ReviewBiomolecules2020
Bullous Pemphigoid: Trigger and Predisposing Factors.
Review in Biomolecules, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 105 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
105 citing papers in PubMed, 4 syntheses or guidelines pooled it, 160 citations in OpenAlex.
- New-onset or flare-up of bullous pemphigoid associated with COVID-19 vaccines: a systematic review of case report and case series studies.Frontiers in medicine · 2024Pooled it
- Pemphigoid diseases in patients with end-stage kidney diseases: pathogenesis and treatment.Frontiers in immunology · 2024Pooled it
- Necrotizing Fasciitis-Severe Complication of Bullous Pemphigoid: A Systematic Review, Risk Factors, and Treatment Challenges.Medicina (Kaunas, Lithuania) · 2023Pooled it
- Association of HLA class II alleles and haplotypes with bullous and mucus membrane pemphigoid risk: A systematic review, a meta-analysis and a meta-regression.International journal of immunopathology and pharmacologyPooled it
- Selective Expansion of TCR Vβ2Experimental dermatology · 2026Article
- A rare case of keloid combined with bullous pemphigoid.Dermatology reports · 2026Article
- Dupilumab for Treatment-refractory Bullous Pemphigoid: A Case Series of Six Patients.Acta dermato-venereologica · 2026Article
- Distinctive Reactivity to the C-terminal Epitope of BP180 Characterizes Immune Checkpoint Inhibitor-associated Bullous Pemphigoid, and an ELISA Based on the BP180 Ectodomain Enables Prompt Diagnosis in a Subset of Patients.Acta dermato-venereologica · 2026Article
- A Multicenter Analysis of Patients with Bullous Pemphigoid: Clinical Characteristics and Insights into Drug-Associated Disease.International journal of molecular sciences · 2026Article
- Bullous pemphigoid following adjuvant radiotherapy for breast cancer: a case report.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026Article
- Association of immune checkpoint inhibitor-induced bullous pemphigoid with underlying cancer type: A lack of association with cancer tissueJID innovations : skin science from molecules to population health · 2026Article
- Localized Bullous Pemphigoid Triggered by Surgical Trauma: A Case Highlighting the Koebner Phenomenon.Cureus · 2026Article
- huSA: a comprehensive database for multi-dimensional resolution of bulk, single cell and spatial transcription profiles in skin diseases.Database : the journal of biological databases and curation · 2026Article
- Secondary Syphilis With Concomitant Bullous Pemphigoid: A Case Report.Case reports in dermatological medicine · 2026Article
- From scalpel to blister: a diagnostic challenge of localized bullous pemphigoid following orthopaedic surgery.Postepy dermatologii i alergologii · 2026Article
- Pemphigoid associated with quinolone antibiotics: a real-world pharmacovigilance study of the FDA adverse event reporting system and literature-based evidence.Frontiers in immunology · 2026Article
- Case Report: Lung transplant recipient with bullous pemphigoid and antibody-mediated rejection: an overlapping immunologic phenomenon?Frontiers in transplantation · 2026Article
- A Case of Nivolumab-Induced Bullous Pemphigoid-Successfully Treated with Rituximab.Journal of community hospital internal medicine perspectives · 2026Article
- Association ofInternational journal of molecular sciences · 2025Article
- Expanding the Spectrum of Bullous Pemphigoid in Skin of Color.Indian dermatology online journal · 2025Article
45 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Bullous pemphigoid (BP) is the most frequent autoimmune subepidermal blistering disease provoked by autoantibodies directed against two hemidesmosomal proteins: BP180 and BP230. Its pathogenesis depends on the interaction between predisposing factors, such as human leukocyte antigen (HLA) genes, comorbidities, aging, and trigger factors. Several trigger factors, such as drugs, thermal or electrical burns, surgical procedures, trauma, ultraviolet irradiation, radiotherapy, chemical preparations, transplants, and infections may induce or exacerbate BP disease. Identification of predisposing and trigger factors can increase the understanding of BP pathogenesis. Furthermore, an accurate anamnesis focused on the recognition of a possible trigger factor can improve prognosis by promptly removing it.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.